02:30 PM EDT, 03/24/2025 (MT Newswires) -- Unity Biotechnology ( UBX ) shares were down nearly 30% in recent trading on Monday after the company said UBX1325, its diabetic macular edema treatment for patients with poor vision, did not achieve statistical non-inferiority at the primary analysis endpoint in the phase 2b Aspire study.

The company said UBX1325 was non-inferior to aflibercept at week 24 with a confidence interval above 90% but did not meet statistical non-inferiority on the average of weeks 20 and 24, reaching an 88% confidence interval instead of the pre-specified 90% threshold.

Unity Biotechnology ( UBX ) posted topline results from all participants through 24 weeks and expects complete 36-week data results in Q2.

Price: 1.28, Change: -0.55, Percent Change: -29.86